Skip to main content
Signal8
Launch Terminal

Protara Therapeutics, Inc. (TARA)

Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Protara Therapeutics, Inc. logo

Protara Therapeutics, Inc.

NASDAQ:TARAHealthcare
-1.59%$2.48
AH$2.52+1.61%vs close
Mkt Cap$146.56M
Float57.78M
O/S59.1M
Vol
$ Vol
RVOL
Inst Own77.9%
Earnings
Dilution
Protara Therapeutics, Inc. logoNASDAQ:TARA$2.48-1.59%
Phase Distribution
15 lead-sponsored trials·4 active·10 completed
Phase 15
Phase 1/22
Phase 23
Phase 2/31
Phase 33
Not applicable1
Status Overview
Recruiting4
Completed10
Stopped1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 3
    Completed

    A Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-1)

    PRT-201, Placebo

    Chronic Kidney Disease

    Enrollment
    349
    Start
    Jul 2014
    Primary Completion
    Dec 2016
    Completion
    Dec 2018
    NCT02110901
  • Phase 3
    Completed

    A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)

    Vonapanitase, Placebo

    Chronic Kidney Disease

    Enrollment
    696
    Start
    Aug 2015
    Primary Completion
    Feb 2018
    Completion
    May 2019
    NCT02414841
  • Phase 3
    Recruiting

    Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer

    TARA-002, Investigator's Choice of Intravesical Chemotherapy

    Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma +1

    Enrollment
    284
    Start
    May 2026
    Primary Completion
    Apr 2028est.
    Completion
    Nov 2032est.
    NCT07480356
  • Phase 2/3
    Recruiting

    Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral Support

    Choline Chloride for Injection, Placebo

    Choline Deficiency, Liver Injury

    Enrollment
    129
    Start
    Dec 2025
    Primary Completion
    Mar 2028est.
    Completion
    Jan 2029est.
    NCT06910943
  • Phase 2
    Completed

    A Study of PRT-201 Administered Immediately After Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease

    PRT-201, Placebo

    Chronic Kidney Disease

    Enrollment
    151
    Start
    Mar 2011
    Primary Completion
    Nov 2012
    Completion
    Nov 2012
    NCT01305824
  • Phase 2
    Recruiting

    Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age

    TARA-002

    Lymphatic Malformation

    Enrollment
    38
    Start
    Oct 2023
    Primary Completion
    Dec 2026est.
    Completion
    May 2027est.
    NCT05871970
  • Phase 2
    Recruiting

    Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

    TARA-002

    Non-muscle Invasive Bladder Cancer

    Enrollment
    131
    Start
    Sep 2023
    Primary Completion
    Oct 2031est.
    Completion
    Mar 2032est.
    NCT05951179
  • Phase 1/2
    Completed

    A Phase 1-2 Study of PRT-201 Administered in Chronic Kidney Disease (CKD) Patients

    PRT-201, PRT-201

    Chronic Kidney Disease

    Enrollment
    66
    Start
    Nov 2008
    Primary Completion
    Jul 2011
    Completion
    Jul 2011
    NCT00679991
  • Phase 1/2
    Completed

    A Study of PRT-201 Administered After Arteriovenous Graft (AVG) Creation in Patients With Chronic Kidney Disease

    PRT-201, Placebo

    Chronic Kidney Disease

    Enrollment
    89
    Start
    Sep 2009
    Primary Completion
    Nov 2012
    Completion
    Nov 2012
    NCT01001351
  • Phase 1
    Completed

    Pilot Study of PRT-201 Following Angioplasty in Patients With Peripheral Artery Disease (PAD)

    PRT-201

    Peripheral Artery Disease

    Enrollment
    14
    Start
    Oct 2012
    Primary Completion
    Jun 2014
    Completion
    Jul 2015
    NCT01616290
  • Phase 1
    Withdrawn

    Safety/ Feasibility of Percutaneous Administration of Vonapanitase as Monotherapy for Peripheral Artery Disease (PAD) of the SFA and Popliteal Arteries

    vonapanitase

    Peripheral Artery Disease

    Enrollment
    0
    Start
    -
    Primary Completion
    Apr 2019
    Completion
    Apr 2019
    NCT02953496
  • Phase 1
    Completed

    Safety/Feasibility of Vonapanitase Following Angioplasty for Patients With Peripheral Artery Disease (PAD) Below the Knee (BTK)

    vonapanitase, Placebo

    Peripheral Artery Disease

    Enrollment
    29
    Start
    Nov 2016
    Primary Completion
    Apr 2019
    Completion
    Apr 2019
    NCT02956993
  • Phase 1
    Completed

    Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)

    TARA-002

    Non-muscle Invasive Bladder Cancer

    Enrollment
    12
    Start
    Mar 2022
    Primary Completion
    Sep 2024
    Completion
    Oct 2024
    NCT05085977
  • Phase 1
    Completed

    Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b)

    TARA-002

    Non-muscle Invasive Bladder Cancer

    Enrollment
    10
    Start
    May 2023
    Primary Completion
    Sep 2024
    Completion
    Sep 2024
    NCT05085990
  • Observational
    Completed

    Prevalence of Liver Disease in Patients Dependent on Parenteral Nutrition

    -

    Intestinal Failure-associated Liver Disease

    Enrollment
    80
    Start
    Aug 2021
    Primary Completion
    Jun 2023
    Completion
    Jun 2023
    NCT05011370
Search ClinicalTrials.gov for “Protara Therapeutics”